Survodutide is a multi‑agonist peptide that combines GLP‑1R agonism (satiety and glycemic modulation) with GCGR agonism (increased lipolysis and energy expenditure), producing a coordinated effect on caloric intake and fat metabolism that is being investigated for robust weight loss and hepatic metabolic benefits in translational studies.
Survodutide is a multi‑agonist peptide that combines GLP‑1R agonism (satiety and glycemic modulation) with GCGR agonism (increased lipolysis and energy expenditure), producing a coordinated effect on caloric intake and fat metabolism that is being investigated for robust weight loss and hepatic metabolic benefits in translational studies.
